A New Paradigm for Immune Modulation

Immunyx is a drug development company focused on neutrophil modulation in disease.

The Challenge:
Neutrophil Therapy

Neutrophils are the most populous immune cell, yet few advances have been made in modulating their disease-causing activity.

Large pharma is working on neutrophil therapies such as Danirixin and Navarixin.

Currently there are no FDA approved neutrophil therapies due to Neutropenia, systemic toxicity and difficulty reaching neutrophils at target location.

Neutrophils

The Need

Effective and safe treatments to prevent deregulated neutrophil damage in numerous large market diseases.

COPD

251m Cases
3.1m Deaths
$11B Market

Cancer

27.5m Cases
9.6m Deaths
$158B Market

Colitis

9m Cases
$10.25B Market

Arthritis

20m Cases
$60B Market

Our Technology:
Targeted Modulation of Neutrophils

Neutrophil modulation via targeted delivery.

Hero image immunyX

Contact Us

Immunyx strives to improve disease treatment. If you’re interested in our mission we would love to hear from you.